Molecular diagnostics firm Biocartis won a €750,000 grant (approximately $796,000) from the Flanders Organization for Innovation & Entrepreneurship (VLAIO) to support the development of a fully ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for ...
New diagnostic test for MSI in solid tumors can inform physicians on immuno-oncology therapies, and can guide treatment decisions for patients with Lynch-associated cancers LEIDEN, Netherlands & ...
Validity of 1% Hormonal Receptor Positivity Cutoff by the ASCO/College of American Pathologists Guidelines at the Georgia Cancer Center In 658 patients with advanced GI cancers who underwent both ...
Mechelen, Belgium, 10 March 2026 - Today, Biocartis announced that its Idylla™ CDx MSI Test has received Class C companion diagnostic (CDx) certification under the EU’s IVDR1 as a CDx for colorectal ...
Clinical performance of liquid RNA (L-RNA) biopsy in a gastrointestinal cancer segment. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results